Pfizer (PFE) Work In Process (2009 - 2019)

Pfizer has disclosed Work In Process across 11 years of filings, most recently posting $5.2 billion for Q1 2019.

• In Q1 2019, Work In Process rose 15.54% year-over-year to $5.2 billion; the TTM figure through Mar 2019 stood at $5.2 billion (up 15.54% YoY), while the FY2018 annual figure was $4.7 billion, up 20.29% from the prior year.
• Work In Process rose to $5.2 billion in Q1 2019, from $4.7 billion in the prior quarter.
• Over the last five years, Work In Process for PFE reached as high as $5.2 billion in Q1 2019 and fell as low as $3.4 billion in Q1 2015.
• The 5-year median for Work In Process is $4.0 billion (2016), against an average of $4.2 billion.
• Annual changes were most pronounced in 2015 — Work In Process advanced 21.06% — and 2016, when it dropped 6.0%.
• A 5-year view of Work In Process shows it stood at $3.9 billion in 2015, then dropped by 6.0% to $3.7 billion in 2016, then gained by 5.74% to $3.9 billion in 2017, then climbed by 20.29% to $4.7 billion in 2018, then gained by 10.23% to $5.2 billion in 2019.
• According to Business Quant data, Work In Process over the past three periods registered $5.2 billion, $4.7 billion, and $4.8 billion for Q1 2019, Q4 2018, and Q3 2018 respectively.